Core Viewpoint - The leading company in traditional Chinese medicine, China Traditional Chinese Medicine (CTCM), has issued a rare profit warning, predicting a loss of between 350 million to 500 million yuan for the fiscal year 2025, marking its first loss in a decade and a significant decline in profitability [1][13]. Group 1: Financial Performance - CTCM's net profit is expected to plummet by 1785% to 2507% year-on-year, with a 45% to 55% decline in profit even after excluding goodwill impairment [1][13]. - The company has experienced a compound annual growth rate (CAGR) of 22.95% in revenue from 2017 to 2021, benefiting from policy incentives for Chinese medicine formula granules [1][13]. Group 2: Business Segment Analysis - The Chinese medicine formula granules segment, which constitutes nearly half of CTCM's total revenue, has seen a revenue drop of 23.5% to approximately 6.97 billion yuan in 2024, and a further decline of 14.1% to about 2.99 billion yuan in the first half of 2025 [4][16]. - The decline in revenue is attributed to increased competition and the impact of centralized procurement, which has led to a significant reduction in income and profitability [4][16]. Group 3: Market Dynamics - The market for Chinese medicine formula granules peaked at 24 billion yuan in 2021 but has since stabilized between 16 billion to 17 billion yuan [5][17]. - A centralized procurement policy introduced in the second half of 2023 has resulted in an average price drop of 50.77% across 22 provinces, further pressuring the revenue and profit margins of CTCM [5][17]. Group 4: Broader Industry Impact - Other companies in the same sector, such as Hongri Pharmaceutical, are also facing significant declines, with a 95.76% drop in net profit in 2024 [6][18]. - CTCM's other business segments, including traditional Chinese medicine production and health products, have also reported varying degrees of revenue decline, with the largest drop of 40.9% in the traditional Chinese medicine production segment [6][18]. Group 5: Strategic Considerations - CTCM is focusing on transformation, emphasizing innovation in traditional Chinese medicine and secondary development of proprietary medicines, with plans to expand its reach to over 1,750 secondary medical institutions in 2025 [7][19]. - The company has undergone multiple mergers and acquisitions to strengthen its industrial base, but the ongoing performance challenges raise questions about its future strategic direction and potential privatization [8][20].